Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Heritage Pharmacueticals Inc. D/B/A Avet Pharmacueticals Inc	23155084012	DICLOFENAC POTASSIUM 25MG 120CT CAPSULES	2022-12-19	1609.1100	None	1	10000	None	None	None	None	None	None	10000 patients on an annual basis. Estimate based on customer volumes.	None
Hikma Pharmaceuticals USA Inc	00143939210	Remifentanil HCl for Injection, 2mg/5mL	2022-01-04	1225.0000	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	36241815	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Remifentanil Hydrochloride for injection is an opioid agonist indicated for intravenous administration: (1) as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. According to the American Hospital Association, there were approximately 36,241,815 admissions to U.S. Hospitals.	None
Hikma Pharmaceuticals USA Inc	00054071119	Deferiprone Tablets, 1000mg, bottle of 50	2022-02-11	6975.5800	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	125000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Deferiprone is indicated for the treatment of patients with trans-fusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, as well as sickle cell anemia disorders.	None
Hikma Pharmaceuticals USA Inc	00143939310	Remifentanil HCl for Injection, 5mg, 10 vials	2022-06-02	2600.0000	This drug is a generic product, therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	36241815	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Remifentanil Hydrochloride for injection is an opioid agonist indicated for intravenous administration: (1) as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. According to the American Hospital Association, there were approximately 36,241,815 admissions to U.S. Hospitals.	None
Horizon Therapeutics USA, Inc.	75987015003	Injection 100 MG/10 ML	2022-05-30	131000.0000	Uplizna is the first and only B-cell depleter approved for the treatment adult patients with AQP4+ neuromyelitis optica spectrum disorder (NMOSD). Horizon’s approach to marketing includes a focus on educating healthcare professionals, primarily neurologists, about the devastating effects of this rare disease and providing information about the efficacy, safety and dosing of Uplizna. Marketing includes dissemination of print materials, digital advertising, in-person presentations and virtual engagements. In addition to healthcare professionals, Horizon also provides educational resources and support to the patient community in collaboration with advocacy organizations. Horizon’s approach to pricing innovative therapies is driven by the value a drug brings to customers. Leading up to FDA approval, the company engaged with key stakeholders—including patients, payers and physicians—to better understand the value this medicine could bring to people affected by NMOSD, who despite recent innovation, have limited treatment options.	None	10000	1	None	2021-03-15	3000000000.0000	None	In March 2021, Horizon completed the acquisition of Viela, in which Horizon acquired all of the issued and outstanding shares of Viela’s common stock for $53.00 per share in cash. The total consideration for the acquisition was approximately $3.0 billion, including cash acquired of $342.3 million.	None	None